Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells.
Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, Taniue K, Katou Y, Shirahige K, Todo T, Ino Y, Mukasa A, Saito N, Matsui M, Takahashi R, Hoshino-Okubo A, Sugano H, Manabe E, Funato K, Akiyama T. Koyama-Nasu R, et al. Among authors: haruta r. Oncogene. 2014 Apr 24;33(17):2236-44. doi: 10.1038/onc.2013.168. Epub 2013 May 20. Oncogene. 2014. PMID: 23686309
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer.
Shigematsu H, Kadoya T, Kobayashi Y, Kajitani K, Sasada T, Emi A, Masumoto N, Haruta R, Kataoka T, Oda M, Arihiro K, Okada M. Shigematsu H, et al. Among authors: haruta r. World J Surg Oncol. 2011 Nov 7;9:146. doi: 10.1186/1477-7819-9-146. World J Surg Oncol. 2011. PMID: 22059982 Free PMC article.
Granular cell tumor of the breast: report of a case.
Kohashi T, Kataoka T, Haruta R, Sugino K, Marubayashi S, Yahata H, Asahara T, Fujii S, Arihiro K, Dohi K. Kohashi T, et al. Among authors: haruta r. Hiroshima J Med Sci. 1999 Mar;48(1):31-3. Hiroshima J Med Sci. 1999. PMID: 10213961
20 results